A carregar...
Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: Is it cost-effective?
OBJECTIVE: Evaluate the cost-effectiveness of incorporating bevacizumab into the treatment regimen for recurrent, persistent, or advanced stage carcinoma of the cervix following publication of a recent phase III trial that demonstrated an overall survival (OS) benefit with the addition of bevacizuma...
Na minha lista:
| Publicado no: | Gynecol Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5553065/ https://ncbi.nlm.nih.gov/pubmed/25448456 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.11.003 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|